This week, six pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
NuPathe Inc. (PATH) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.
GW Pharmaceuticals PLC Sponsored ADR (GWPH) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of GWPH stock.
Watson Pharmaceuticals (WPI) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Paratek Pharmaceuticals Inc (PRTK) shows solid improvement this week. The company’s rating rises from a B to an A. For more information, get Portfolio Grader’s complete analysis of PRTK stock.
This is a strong week for Cardiome Pharma (CRME). The company’s rating climbs to B from the previous week’s C. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. For more information, get Portfolio Grader’s complete analysis of CRME stock.
AbbVie, Inc.’s (ABBV) ratings are looking better this week, moving up to a B from last week’s C. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
